Different Perspectives of Patients and Physicians on LDL-C Target Achievement in the Treatment of Hypercholesterolemia: Results on Secondary Prevention from the German PROCYON Survey

• Published in: Advances in therapy Vol. 40; no. 2; pp. 460 - 473
• Main Authors: Makhmudova, Umidakhon, Wolf, Michaela, Willfeld, Kathy, Beier, Lea, Weingärtner, Oliver
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.02.2023
• Subjects: Animals; Cardiology; Cholesterol, LDL; Endocrinology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - drug therapy; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Physicians; Raccoons; Rheumatology; Secondary Prevention; Surveys and Questionnaires; Low-density lipoprotein; Secondary prevention; Hypercholesterolemia; Patient management
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-022-02357-1

Aims Low-density lipoprotein cholesterol (LDL-C) reduction in hypercholesterolemia patients at very high cardiovascular (CV) risk is essential in preventing future CV events. The objective was to assess the perception on hypercholesterolemia management in secondary prevention in Germany. Methods PROCYON was a two-part online survey, including a patient questionnaire as well as a physician questionnaire. Results A total of 109 general practitioners, internists, and cardiologists participated. The current ESC/EAS recommendation for high-risk patients is followed by 19.3% of the physicians. The majority (80.7%) reported an LDL-C target failure rate of at least 30%. More than two thirds (71.6%) have stated treating less than half of their patients with the maximum approved statin dose. The survey included 1696 secondary prevention patients. The majority (86.7%) consult their general practitioner for hypercholesterolemia; 54.0% consult a cardiologist (multiple answers allowed). Most patients (87.0%) were receiving lipid-lowering medication. Among these, 800 (54.2%) reported improved LDL-C levels since diagnosis, 569 (38.6%) reported no improvement, and 106 (7.2%) had no information. Of the treated patients with ( N ’ = 800) and without ( N ’ = 569) improvement, 34.3% vs. 37.3% were on their initial drug and dose, 24.8% vs. 23.7% received multiple drug therapy, 48.9% vs. 48.9% reported a dose change, and 16.1% vs. 14.2% had discontinued at least one drug (multiple answers). Disease knowledge was rated as good or very good by 29.8% of patients. Conclusion PROCYON demonstrated insufficient ESC/EAS guideline implementation regarding target levels and therapeutic escalation strategies. Furthermore, a lack of specialist involvement and patient education was identified.